Overexpression and altered glycosylation of MUC1 in malignant mesothelioma

British Journal of Cancer

Volumn 98, Issue 9, 2008, Pages 1562-1569

  Creaney, J ^a,b,g   Segal, A ^c   Sterrett, G ^c,d   Platten, M A ^c   Baker, E ^e,f   Murch, A R ^d,e   Nowak, A K ^b,g   Robinson, B W S ^a,b   Millward, M J ^b,g  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e KING EDWARD MEMORIAL HOSPITAL   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Diagnosis; EMA; Mesothelioma; MUC 1

Indexed keywords

CA 15-3 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; MESSENGER RNA; MUCIN 1; MUCIN 1 ANTIBODY; PROTEIN ANTIBODY;

ADULT; AGED; ARTICLE; CELL SURFACE; CONTROLLED STUDY; EFFUSION; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RNA SPLICING; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; CA-15-3 ANTIGEN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 43249083136     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604340     Document Type: Article

References (31)

1. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S (2001) Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 31: 9-16
2. Baldus SE, Engelmann K, Hanisch FG (2004) MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41: 189-231
3. Baeckstrom D, Nilsson O, Price MR, Lindholm L, Hansson GC (1993) Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody. Cancer Res 53(4): 755-761
4. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108
5. Cao Y, Cao Y, Karsten U, Hilgers J (1998) Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues. Tumour Biol 19(Suppl 1): 88-99
6. Cordell J, Richardson TC, Pulford KA, Ghosh AK, Gatter KC, Heyderman E, Mason DY (1985) Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer 52(3): 347-354
7. Hanisch FG (1998) Specificity clusters of MUC1-reactive mouse monoclonal antibodies. Tumour Biol 19(Suppl 1): 111-117
8. Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD (2006) A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 12: 5129-5135
9. Klee GG, Schreiber WE (2004) MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med 128: 1131-1135
10. Light RW, Macgregor MI, Luchsinger PC, Ball Jr WC (1972) Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77: 507-513
11. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12: 869-877
12. Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, Reyre J, Carles P, Serre G (1999) Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 81: 1059-1065
13. Miles D, Papazisis K (2003) Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 3(Suppl 4): S134-S138
14. Morse MA (2001) Technology evaluation: BLP-25, Biomira Inc.. Curr Opin Mol Ther 3: 102-105
15. North SA, Graham K, Bodnar D, Venner P (2006) A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 176: 91-95
16. Obermair A, Schmid BC, Packer LM, Leodolter S, Birner P, Ward BG, Crandon AJ, McGuckin MA, Zeillinger R (2002) Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 100: 166-171
17. Ohuchida K, Mizumoto K, Yamada D, Fujii K, Ishikawa N, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M (2006) Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int J Cancer 118: 405-411
18. Ordonez NG (2003) The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27: 1031-1051
19. Peterson JA, Couto JR, Taylor MR, Ceriani RL (1995) Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer. Cancer Res 55: 5847s-5851s
20. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18: 1295-1304
21. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366: 397-408
22. Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA, Miyazaki K, Kenemans P, Hilgers J (2000) Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumour Biol 21(4): 197-210
23. Saad RS, Cho P, Liu YL, Silverman JF (2005) The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 32: 156-159
24. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR (2005) Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 10: 501-507
25. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M (2002) MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7: 209-221
26. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S (2004) Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 44: 147-155
27. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz-Alfaro J (2003) Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 40: 289-294
28. Whitaker D (2000) The cytology of malignant mesothelioma. Cytopathology 11: 139-151
29. Wierecky J, Mueller M, Brossart P (2006a) Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55: 63-67
30. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L, Brossart P (2006b) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918
31. Wolanski KD, Whitaker D, Shilkin KB, Henderson DW (1998) The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82: 583-590